The group’s principal activity is to provide biotechnology treatment therapies. The group provides treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. The group provides concept data in animal models of diseases include asthma, macular degeneration, immune renal disease, inflammatory arthritis, ischemia-reperfusion injury, stroke and traumatic brain injury. The group operates from the United States.
